However, regrettably, no functional differences were found between the treated and untreated groups after a study period of 12 months duration. In addition, while in the placebo group one death occurred (5%) there were eight deaths in the rasagiline group (13.3%, reported to have not reached statistically significance) and 30 of the original 80 patients discontinued the study (60% in the placebo and 30% in the rasagiline group). Of note that there was also no significant difference between rasagiline-treated and placebo-treated platelet TDP-43, survival at 12 months between the rasagiline, placebo, or (to increase study power) historical controls (n=177), defined as a comparison between a new treatment in a current patient cohort with an old treatment in a previous cohort \cite{Baker2001} ). The importance of TDP-43 and the inability of the drug, at concentration given (2 mg/day) for 12 months, to modulate the levels of the protein may have a role in the drugs failure to impact survivability, although there are clearly other possibilities, such as potentially the power or duration of the study. There is some indication of this as there was another double blind, placebo controlled phase II multi-center clinical trial which reported a slowing of disease progression in patients with "possible, probable or definite" ALS with rasagiline 1mg/day for up to 18 months as an add on to riluzole at 100 mg/day, with the primary endpoint being survival prolongation (not found) and secondary endpoint being ALSFRS, which post-hoc analysis indicated a trend toward slowing of disease progress (clinicaltrials.gov identifier NCT01879241 ) \cite{Ludolph2018}.